Company intelligence / Profile preview

Allastir

Waltham, Massachusetts, United Statesallastir.com ↗

Ownership: Private
Development stage: Other

Overview

Allastir is a biotechnology company focused on developing novel therapies that target the alarmin pathway to treat severe inflammatory and respiratory diseases. The company's primary focus is on Interleukin-33 (IL-33), a key initiator of the inflammatory cascade in conditions such as asthma and COPD. By inhibiting IL-33, Allastir aims to provide more effective treatments for patients who do not respond to current standard-of-care therapies. The company was founded by experienced industry veterans and is backed by leading life science venture capital firms including Polaris Partners and ARCH Venture Partners.

Therapeutic areas: PulmonologyDermatology
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

3 assets

ubiquinol acetate

Unknown

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Allastir.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allastir.

Explore the full profile